Lumos Diagnostics Holdings Limited logo

Lumos Diagnostics Holdings Limited (LDX)

Market Closed
ASX ASX
- Market Cap
- P/E Ratio
- Div Yield
199,316 Volume
0 Eps
Want to track LDX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

LDX is not paying dividends to its shareholders.
The last earnings report, released on Feb 23, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Lumos Diagnostics Holdings Limited has completed 2 stock splits, with the recent split occurring on Sep 06, 2024.
The company's stock is traded on 4 different exchanges and in various currencies, with the primary listing on ASX (AUD).

Lumos Diagnostics Holdings Limited (LDX) FAQ

On which exchange is it traded?

Lumos Diagnostics Holdings Limited is listed on ASX.

What is its stock symbol?

The ticker symbol is LDX.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has Lumos Diagnostics Holdings Limited ever had a stock split?

Lumos Diagnostics Holdings Limited had 2 splits and the recent split was on Sep 06, 2024.

Lumos Diagnostics Holdings Limited Profile

Professional Services Industry
Industrials Sector
Douglas Ward CEO
ASX Exchange
AU0000157091 ISIN
AU Country
- Employees
- Last Dividend
6 Sep 2024 Last Split
- IPO Date

Overview

Lumos Diagnostics Holdings Limited is a pioneering contract research and development firm with a sharp focus on the creation, manufacturing, and commercialization of rapid point-of-care (POC) diagnostic products. These products are essential for the diagnosis and management of infectious diseases, with operations spanning the United States and Australia. Founded in 2004 and headquartered in Melbourne, Australia, Lumos Diagnostics aims to enhance global healthcare by providing quick and reliable diagnostic solutions.

Products and Services

  • FebriDx

    FebriDx stands as a pivotal POC diagnostic test designed for the swift detection and differentiation of viral and bacterial respiratory infections. This innovative product aids healthcare professionals in making informed decisions concerning treatment strategies, facilitating appropriate antibiotic use and reducing the spread of infections.

  • ViraDx

    ViraDx is a comprehensive three-in-one POC test capable of simultaneously detecting influenza A, influenza B, and COVID-19. This test is particularly valuable for its ability to differentiate among these prevalent respiratory viruses, ensuring timely and accurate medical interventions during flu seasons and pandemic outbreaks.

  • CoviDx

    CoviDx is a specialized rapid antigen test for COVID-19, developed to provide quick results concerning COVID-19 infection status. By offering results in a matter of minutes, CoviDx plays a crucial role in the fast tracking of testing and isolation procedures, thus helping to control the spread of the virus effectively.

  • Desktop Readers, Disposable Readers, and Lumos Leelu Readers

    Lumos Diagnostics also offers a range of reader devices, including desktop, disposable, and the unique Lumos Leelu readers. These devices are designed to work in tandem with the company's diagnostic tests, enhancing the precision, reliability, and user-friendliness of the test results. These readers are integral to the ecosystem of Lumos Diagnostics’ solutions, providing healthcare professionals with advanced tools to interpret test outcomes accurately.

Contact Information

Address: Level 4
Phone: 61 3 9087 1598